Eyenovia Announces $12 Million Registered Direct Offering
August 24, 2023 18:47 ET
|
Eyenovia, Inc.
NEW YORK, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a commercial-stage ophthalmic technology company commercializing Mydcombi™ (tropicamide+phenylephrine ophthalmic spray for...
Eyenovia Acquires U.S. Commercial Rights to APP13007 (Clobetasol Propionate Ophthalmic Nanosuspension, 0.05%) from Formosa Pharmaceuticals
August 16, 2023 06:00 ET
|
Eyenovia, Inc.
APP13007, if approved, may have an advantageous profile in dosing frequency and side effects while reducing the inflammation and pain associated with ocular surgery Further leverages Eyenovia’s...
Eyenovia Reports Second Quarter 2023 Financial Results and Provides Business Update
August 10, 2023 16:05 ET
|
Eyenovia, Inc.
Announced FDA approval of and first commercial sale of Mydcombi™, the only fixed dose combination of tropicamide and phenylephrine for mydriasis and the first FDA approved product to utilize the...
Eyenovia to Present at Upcoming H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference
August 09, 2023 08:00 ET
|
Eyenovia, Inc.
NEW YORK, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (Nasdaq: EYEN), an ophthalmic technology company commercializing Mydcombi™ (tropicamide and phenylephrine hydrochloride ophthalmic spray)...
Eyenovia to Report Second Quarter 2023 Results on Thursday, August 10
August 07, 2023 08:00 ET
|
Eyenovia, Inc.
NEW YORK, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic technology company commercializing Mydcombi™ (tropicamide+phenylephrine ophthalmic spray) for mydriasis and...
Eyenovia Announces First Commercial Sale of Mydcombi™
August 03, 2023 08:00 ET
|
Eyenovia, Inc.
Represents the first FDA approved and commercially available fixed combination of tropicamide and phenylephrine for pupil dilation Validates Eyenovia’s proprietary Optejet® dispensing platform ...
Eyenovia Announces Addition to Russell 2000® and Russell 3000® Indexes
June 26, 2023 08:00 ET
|
Eyenovia, Inc.
NEW YORK, June 26, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a commercial-stage ophthalmic technology company preparing for the launch of Mydcombi™ (tropicamide+phenylephrine...
Eyenovia Announces Presentation at the OCTANE Ophthalmology Tech Forum 2023
June 01, 2023 08:00 ET
|
Eyenovia, Inc.
Presentation to highlight recent FDA approval of Mydcombi™ for mydriasis which leverages Eyenovia’s novel Optejet dispensing device Optejet represents the first true advancement in the topical...
Eyenovia Reports First Quarter 2023 Financial Results and Provides Business Update
May 11, 2023 16:05 ET
|
Eyenovia, Inc.
Announced FDA approval of Mydcombi™, a fixed dose combination of tropicamide and phenylephrine for mydriasis, the first FDA approved product to utilize the Optejet® Received feedback from FDA on...
Eyenovia Announces FDA Approval of Mydcombi™, the First Ophthalmic Spray for Mydriasis, Which Also Leverages the Company’s Proprietary Optejet® Device Platform
May 08, 2023 08:00 ET
|
Eyenovia, Inc.
Represents the first FDA approved fixed-combination of tropicamide and phenylephrine for mydriasis Provides critical validation of key technology that is core to Eyenovia’s proprietary development...